Treatment of erectile dysfunction in adult males.
In order for Tadalafil to be effective for the treatment of erectile dysfunction,
sexual stimulation is required.
Torlen is not indicated for use by women.

Erectile dysfunction in adult Men
In general, the recommended dose is 10mg taken prior to anticipated sexual
activity and with or without food. In those patients in whom Tadalafil 10mg does
not produce an adequate effect, 20mg might be tried. It may be taken at least 30
minutes prior to sexual activity.
The maximum dose frequency is once per day.
Tadalafil 10mg and 20mg is intended for use prior to anticipated sexual activity
and it is not recommended for continuous daily use.
In patients who anticipate a frequent use of Tadalafil (i.e., at least twice weekly) a
once daily regimen with the lowest doses of Tadalafil might be considered
suitable, based on patient choice and the physician's judgment.
In these patients, the recommended dose is 5mg taken once a day at
approximately the same time of day. The dose may be decreased to 2.5mg once a
day based on individual tolerability.
The appropriateness of continued use of the daily regimen should be reassessed
periodically.
Benign prostatic hyperplasia in adult men
The recommended dose is 5 mg, taken at approximately the same time every day
with or without food. For adult men being treated for both benign prostatic
hyperplasia and erectile dysfunction the recommended dose is also 5 mg taken at
approximately the same time every day. Patients who are unable to tolerate
Tadalafil 5 mg for the treatment of benign prostatic hyperplasia should consider
an alternative therapy as the efficacy of Tadalafil 2.5mg for the treatment of
benign prostatic hyperplasia has not been demonstrated.
Special Populations
Elderly Men
Dose adjustments are not required in elderly patients.
Men with Renal Impairment
Dose adjustments are not required in patients with mild to moderate renal
impairment. For patients with severe renal impairment, 10mg is the maximum
recommended dose for on-demand treatment. Once-a-day dosing of 2.5 or 5 mg
tadalafil both for the treatment of erectile dysfunction or benign prostatic
hyperplasia is not recommended in patients with severe renal impairment. (See
sections 4.4 and 5.2.)
Men with Hepatic Impairment
For the treatment of erectile dysfunction using on-demand Torlen the
recommended dose of Torlen is 10mg taken prior to anticipated sexual activity
and with or without food. There is limited clinical data on the safety of Torlen in
patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a
careful individual benefit/risk evaluation should be undertaken by the
prescribing physician. There are no available data about the administration of
doses higher than 10mg of tadalafil to patients with hepatic impairment. Once-aday
dosing of Torlen both for the treatment of erectile dysfunction and benign
prostatic hyperplasia has not been evaluated in patients with hepatic impairment;
therefore if prescribed, a careful individual benefit/risk evaluation should be
undertaken by the prescribing physician. (See sections 4.4 and 5.2.)
Men with Diabetes
Dose adjustments are not required in diabetic patients.
Paediatric population
There is no relevant use of Tadalafil in the paediatric population with regard to
the treatment of erectile dysfunction.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. In clinical studies, Tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and Tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of Torlen to patients who are using any form of organic nitrate is contraindicated. (See section 4.5.) Torlen must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. The following groups of patients with cardiovascular disease were not included in clinical trials and the use of Tadalafil is therefore contraindicated: • Patients with myocardial infarction within the last 90 days. • Patients with unstable angina or angina occurring during sexual intercourse. • Patients with New York Heart Association class 2 or greater heart failure in the last 6 months. • Patients with uncontrolled arrhythmias, hypotension (<90/50mmHg), or uncontrolled hypertension. • Patients with a stroke within the last 6 months. Torlen is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4). • The co-administration of PDE5 inhibitors, including Tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).

Before treatment with Torlen
A medical history and physical examination should be undertaken to diagnose
erectile dysfunction or benign prostatic hyperplasia and determine potential
underlying causes, before pharmacological treatment is considered.
Prior to initiating any treatment for erectile dysfunction, physicians should
consider the cardiovascular status of their patients, since there is a degree of
cardiac risk associated with sexual activity. Tadalafil has vasodilator properties,
resulting in mild and transient decreases in blood pressure (see section 5.1), and
as such potentiates the hypotensive effect of nitrates (see section 4.3).
Prior to initiating treatment with Tadalafil for benign prostatic hyperplasia
patients should be examined to rule out the presence of carcinoma of the prostate
and carefully assessed for cardiovascular conditions (see section 4.3).
The evaluation of erectile dysfunction should include a determination of potential
underlying causes and the identification of appropriate treatment following an
appropriate medical assessment. It is not known if Tadalafil is effective in patients
who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy.
Cardiovascular
Serious cardiovascular events, including myocardial infarction, sudden cardiac
death, unstable angina pectoris, ventricular arrhythmia, stroke, transient
ischaemic attacks, chest pain, palpitations and tachycardia, have been reported
either post marketing and/or in clinical trials. Most of the patients in whom these
events have been reported had pre-existing cardiovascular risk factors. However,
it is not possible to definitively determine whether these events are related
directly to these risk factors, to Tadalafil, to sexual activity, or to a combination of
these or other factors.
Tadalafil (2.5mg and 5mg) - In patients receiving concomitant antihypertensive
medicinal products, Tadalafil may induce a blood pressure decrease. When
initiating daily treatment with Tadalafil, appropriate clinical considerations
should be given to a possible dose adjustment of the antihypertensive therapy.
In patients who are taking alpha1 blockers, concomitant administration of Torlen
may lead to symptomatic hypotension in some patients (see section 4.5). The
combination of Tadalafil and doxazosin is not recommended.
Vision
Visual defects and cases of NAION have been reported in connection with the
intake of Torlen and other PDE5 inhibitors. The patient should be advised that in
case of sudden visual defect, he should stop taking Torlen and consult a physician
immediately (see section 4.3).
Renal and hepatic impairment
Due to increased Tadalafil exposure (AUC), limited clinical experience and the
lack of ability to influence clearance by dialysis, once-a-day dosing of Torlen is
not recommended in patients with severe renal impairment.
There is limited clinical data on the safety of single-dose administration of Torlen
in patients with severe hepatic insufficiency (Child-Pugh class C). Once-a-day
administration either for the treatment of erectile dysfunction or benign prostatic
hyperplasia has not been evaluated in patients with hepatic insufficiency. If
Torlen is prescribed, a careful individual benefit/risk evaluation should be
undertaken by the prescribing physician.
Priapism and anatomical deformation of the penis
Patients who experience erections lasting 4 hours or more should be instructed to
seek immediate medical assistance. If priapism is not treated immediately, penile
tissue damage and permanent loss of potency may result.
Torlen should be used with caution in patients with anatomical deformation of
the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) or in
patients who have conditions which may predispose them to priapism (such as
sickle cell anaemia, multiple myeloma, or leukemia).
Use with CYP3A4 inhibitors
Caution should be exercised when prescribing Torlen to patients using potent
CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and
erythromycin), as increased Tadalafil exposure (AUC) has been observed if the
medicinal products are combined (see section 4.5).
Torlen and other treatments for erectile dysfunction
The safety and efficacy of combinations of Torlen and other PDE5 inhibitors or
other treatments for erectile dysfunction have not been studied. The patients
should be informed not to take Torlen in such combinations.
Lactose
Torlen contains lactose. Patients with rare hereditary problems of galactose
intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
should not take this medicinal product.
Decreased or sudden hearing loss
Cases of sudden hearing loss have been reported after the use of Tadalafil.
Although other risk factors were present in some cases (such as age, diabetes,
hypertension and previous hearing loss history) patients should be advised to
stop taking Tadalafil and seek prompt medical attention in the event of sudden
decrease or loss of hearing.
Hepatic impairment (Tadalafil 10 mg and 20 mg)
There is limited clinical data on the safety of single-dose administration of
Tadalafil in patients with severe hepatic insufficiency (Child-Pugh Class C). If
Tadalafil is prescribed, a careful individual benefit/risk evaluation should be
undertaken by the prescribing physician.

Interaction studies were conducted with 10mg and/or 20mg Tadalafil, as
indicated below. With regard to those interaction studies where only the 10mg
Tadalafil dose was used, clinically relevant interactions at higher doses cannot be
completely ruled out.
Effects of Other Substances on Tadalafil
Cytochrome P450 inhibitors
Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4,
ketoconazole (200mg daily), increased Tadalafil (10mg) exposure (AUC) 2-fold
and Cmax by 15%, relative to the AUC and Cmax values for Tadalafil alone.
Ketoconazole (400mg daily) increased Tadalafil (20mg) exposure (AUC) 4-fold
and Cmax by 22%. Ritonavir, a protease inhibitor (200mg twice daily), which is an
inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased Tadalafil (20mg)
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions
have not been studied, other protease inhibitors, such as saquinavir, and other
CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and
grapefruit juice, should be co-administered with caution, as they would be
expected to increase plasma concentrations of Tadalafil (see section 4.4).
Consequently, the incidence of the adverse reactions listed in section 4.8 might be
increased.
Transporters
The role of transporters (for example, p-glycoprotein) in the disposition of
Tadalafil is not known. Therefore, there is the potential of drug interactions
mediated by inhibition of transporters.
Cytochrome P450 inducers
A CYP3A4 inducer, rifampicin, reduced Tadalafil AUC by 88%, relative to the
AUC values for Tadalafil alone (10mg). This reduced exposure can be anticipated
to decrease the efficacy of Tadalafil; the magnitude of decreased efficacy is
unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and
carbamazepine, may also decrease plasma concentrations of Tadalafil.
Effects of Tadalafil on Other Medicinal Products
Nitrates
In clinical studies, Tadalafil (5mg, 10mg and 20mg) was shown to augment the
hypotensive effects of nitrates. Therefore, administration of Torlen to patients
who are using any form of organic nitrate is contraindicated (see section 4.3).
Based on the results of a clinical study in which 150 subjects received daily doses
of Tadalafil 20mg for 7 days and 0.4mg sublingual nitroglycerin at various times,
this interaction lasted for more than 24 hours and was no longer detectable when
48 hours had elapsed after the last Tadalafil dose. Thus, in a patient prescribed
any dose of Tadalafil (2.5mg - 20mg), where nitrate administration is deemed
medically necessary in a life-threatening situation, at least 48 hours should have
elapsed after the last dose of Tadalafil before nitrate administration is considered.
In such circumstances, nitrates should only be administered under close medical
supervision with appropriate hemodynamic monitoring the
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8mg daily) and Tadalafil (5mg daily
dose and 20mg as a single dose) increases the blood pressure-lowering effect of
this alpha-blocker in a significant manner. This effect lasts at least twelve hours
and may be symptomatic, including syncope. Therefore, this combination is not
recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these
effects were not reported with alfuzosin or tamsulosin. However, caution should
be exercised when using Tadalafil in patients treated with any alpha-blockers,
and notably in the elderly. Treatments should be initiated at minimal dosage and
progressively adjusted.
In clinical pharmacology studies, the potential for Tadalafil to augment the
hypotensive effects of antihypertensive medicinal products was examined. Major
classes of antihypertensive medicinal products were studied, including calciumchannel
blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors
(enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses,
alone or in combination with thiazides, calcium-channel blockers, beta-blockers,
and/or alpha-blockers). Tadalafil (10mg, except for studies with angiotensin II
receptor blockers and amlodipine in which a 20mg dose was applied) had no
clinically significant interaction with any of these classes. In another clinical
pharmacology study, Tadalafil (20mg) was studied in combination with up to 4
classes of antihypertensives. In subjects taking multiple antihypertensives, the
ambulatory-blood-pressure changes appeared to relate to the degree of blood
pressure control. In this regard, study subjects whose blood pressure was well
controlled, the reduction was minimal and similar to that seen in healthy subjects.
In study subjects whose blood pressure was not controlled, the reduction was
greater, although this reduction was not associated with hypotensive symptoms
in the majority of subjects. In patients receiving concomitant antihypertensive
medicinal products, Tadalafil 20mg may induce a blood pressure decrease, which
(with the exception of alpha-blockers - see above) is, in general, minor and not
likely to be clinically relevant. Analysis of Phase 3 clinical trial data showed no
difference in adverse events in patients taking Tadalafil with or without
antihypertensive medicinal products. However, appropriate clinical advice
should be given to patients regarding a possible decrease in blood pressure when
they are treated with antihypertensive medicinal products
5- alpha reductase inhibitors
In a clinical trial that compared Tadalafil 5 mg coadministered with finasteride 5
mg to placebo plus finasteride 5 mg in the relief of BPH symptoms, no new
adverse reactions were identified. However, as a formal drug-drug interaction
study evaluating the effects of Tadalafil and 5-alpha reductase inhibitors (5-ARIs)
has not been performed, caution should be exercised when Tadalafil is coadministered
with 5-ARIs.
CYP1A2 substrates (e.g. theophylline)
When Tadalafil 10mg was administered with theophylline (a non-selective
phosphodiesterase inhibitor) in a clinical pharmacology study, there was no
pharmacokinetic interaction. The only pharmacodynamic effect was a small (3.5
bpm) increase in heart rate. Although this effect is minor and was of no clinical
significance in this study, it should be considered when co-administering these
medicinal products.
Ethinylestradiol and terbutaline
Tadalafil has been demonstrated to produce an increase in the oral bioavailability
of ethinylestradiol; a similar increase may be expected with oral administration of
terbutaline, although the clinical consequence of this is uncertain.
Alcohol
Alcohol concentrations (mean maximum blood concentration 0.08%) were not
affected by co-administration with Tadalafil (10mg or 20mg). In addition, no
changes in Tadalafil concentrations were seen 3 hours after co-administration
with alcohol. Alcohol was administered in a manner to maximize the rate of
alcohol absorption (overnight fast with no food until 2 hours after alcohol).
Tadalafil (20mg) did not augment the mean blood pressure decrease produced by
alcohol (0.7g/kg or approximately 180ml of 40% alcohol [vodka] in an 80 kg male)
but, in some subjects, postural dizziness and orthostatic hypotension were
observed. When Tadalafil was administered with lower doses of alcohol
(0.6g/kg), hypotension was not observed and dizziness occurred with similar
frequency to alcohol alone. The effect of alcohol on cognitive function was not
augmented by Tadalafil (10mg).
Cytochrome P450 metabolised medicinal products
Tadalafil is not expected to cause clinically significant inhibition or induction of
the clearance of medicinal products metabolised by CYP450 isoforms. Studies
have confirmed that Tadalafil does not inhibit or induce CYP450 isoforms,
including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.
CYP2C9 substrates (e.g. R-warfarin)
Tadalafil (10mg and 20mg) had no clinically significant effect on exposure (AUC)
to S-warfarin or R-warfarin (CYP2C9 substrate), nor did Tadalafil affect changes
in prothrombin time induced by warfarin.
Aspirin
Tadalafil (10mg and 20mg) did not potentiate the increase in bleeding time caused
by acetylsalicylic acid.
Antidiabetic medicinal products
Specific interaction studies with antidiabetic medicinal products were not
conducted.
Riociguat
Preclinical studies showed an additive systemic blood pressure lowering effect
when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat
has been shown to augment the hypotensive effects of PDE5 inhibitors. There was
no evidence of favorable clinical effect of the combination in the population
studied. Concomitant use of riociguat with PDE5 inhibitors, including Tadalafil, is
contraindicated (see section 4.3).

Torlen is not indicated for use by women.
Pregnancy
There are limited data from the use of Tadalafil in pregnant women. Animal
studies do not indicate direct or indirect harmful effects with respect to
pregnancy, embryonal/foetal development, parturition or postnatal development
(see section 5.3). As a precautionary measure, it is preferable to avoid the use of
Torlen during pregnancy.
Breastfeeding
Available pharmacodynamic/toxicological data in animals have shown excretion
of Tadalafil in milk. A risk to the suckling child cannot be excluded. Torlen
should not be used during breast feeding.
Fertility
Effects were seen in dogs that might indicate impairment of fertility. Two
subsequent clinical studies suggest that this effect is unlikely in humans, although
a decrease in sperm concentration was seen in some men (see sections 5.1 and
5.3).

Torlen has negligible influence on the ability to drive or use machines. Although
the frequency of reports of dizziness in placebo and Tadalafil arms in clinical
trials was similar, patients should be aware of how they react to Torlen before
driving or using machines.

Summary of the safety profile The most commonly reported adverse reactions in patients taking Tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of Tadalafil. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with Tadalafil once-a-day dosing are experienced within the first 10 to 30 days of starting treatment. Tabulated summary of adverse reactions The table below lists the adverse reactions for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia. Frequency convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1000 to <1/100), Rare (≥1/10,000 to<1/1000), Very Rare (<1/10,000) and Not known (cannot be estimated from the available data).

Very common	Common	Uncommon	Rare
Immune system disorders
		Hypersensitivity reactions	Angioedema2
Nervous system disorders
	Headache	Dizziness	Stroke1 (including hemorrhagic events), Syncope, Transient ischaemic attacks1, Migraine2, Seizures, Transient amnesia
Eye disorders
		Blurred vision, Sensations described as eye pain	Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)2, Retinal vascular occlusion2
Vascular disorders
	Flushing	Hypotension3, Hypertension
Respiratory, thoracic and mediastinal disorders
	Nasal congestion	Dyspnoea, Epistaxis
Gastrointestinal disorders
	Dyspepsia	Abdominal pain, Vomiting, Nausea, Gastro-esophageal reflux
Skin and subcutaneous tissue disorders
		Rash	Urticaria, Stevens-Johnson syndrome2, Exfoliative dermatitis2, Hyperhydrosis (sweating)
Renal and urinary disorders
		Haematuria
Musculoskeletal, connective tissue and bone disorders
	Back pain, Myalgia, Pain in extremity
Reproductive system and breast disorders
		Prolonged erections	Priapism, Penile haemorrhage, Haematospermia
General disorders and administration site conditions
		Chest pain1, Peripheral oedema, Fatigue	Facial oedema2, Sudden cardiac death1,2

1 Most of the patients had pre-existing cardiovascular risk factors (see section 4.4). 2 Post marketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials. 3 More commonly reported when Tadalafil is given to patients who are already taking antihypertensive medicinal products. Description of selected adverse reactions A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in patients treated with Tadalafil once a day as compared with placebo. Most of these ECG abnormalities were not associated with adverse reactions. Other special populations Data in patients over 65 years of age receiving Tadalafil in clinical trials, either for the treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials with Tadalafil 5mg taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age. To reports any side effect(s):  Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC) - Fax: +966-11-205-7662 - Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. - Toll free phone: 8002490000 - E-mail: npc.drug@sfda.gov.sa - Website: www.sfda.gov.sa/npc
 Other GCC States: Please contact the relevant competent authority

Single doses of up to 500mg have been given to healthy subjects, and multiple
daily doses up to 100mg have been given to patients. Adverse events were similar
to those seen at lower doses.
In cases of overdose, standard supportive measures should be adopted, as
required. Haemodialysis contributes negligibly to Tadalafil elimination.

Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC
code: G04BE08.
Mechanism of action
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate
(cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation
causes the local release of nitric oxide, inhibition of PDE5 by Tadalafil produces
increased levels of cGMP in the corpus cavernosum. This results in smooth muscle
relaxation and inflow of blood into the penile tissues, thereby producing an
erection. Tadalafil has no effect in the treatment of erectile dysfunction in the
absence of sexual stimulation.
The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is
also observed in the smooth muscle of the prostate, the bladder and their vascular
supply. The resulting vascular relaxation increases blood perfusion which may be
the mechanism by which symptoms of benign prostatic hyperplasia are reduced.
These vascular effects may be complemented by inhibition of bladder afferent
nerve activity and smooth muscle relaxation of the prostate and bladder.
Pharmacodynamic effects
Studies in vitro have shown that Tadalafil is a selective inhibitor of PDE5. PDE5 is
an enzyme found in corpus cavernosum smooth muscle, vascular and visceral
smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect
of Tadalafil is more potent on PDE5 than on other phosphodiesterases. Tadalafil is
>10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4, enzymes
which are found in the heart, brain, blood vessels, liver, and other organs.
Tadalafil is >10,000-fold more potent for PDE5 than for PDE3, an enzyme found in
the heart and blood vessels. This selectivity for PDE5 over PDE3 is important
because PDE3 is an enzyme involved in cardiac contractility. Additionally,
Tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an
enzyme which is found in the retina and is responsible for phototransduction.
Tadalafil is also >10,000-fold more potent for PDE5 than for PDE7 through PDE10.
Clinical efficacy and safety
Tadalafil administered to healthy subjects produced no significant difference
compared to placebo in supine systolic and diastolic blood pressure (mean
maximal decrease of 1.6/0.8mmHg, respectively), in standing systolic and
diastolic blood pressure (mean maximal decrease of 0.2/4.6mmHg, respectively),
and no significant change in heart rate.
In a study to assess the effects of Tadalafil on vision, no impairment of colour
discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue
test. This finding is consistent with the low affinity of Tadalafil for PDE6
compared to PDE5. Across all clinical studies, reports of changes in colour vision
were rare (<0.1%).
Three studies were conducted in men to assess the potential effect on
spermatogenesis of Tadalafil 10mg (one 6-month study) and 20mg (one 6-month
and one 9-month study) administered daily. In two of these studies decreases
were observed in sperm count and concentration related to Tadalafil treatment of
unlikely clinical relevance. These effects were not associated with changes in other
parameters, such as motility, morphology, and FSH.
Erectile dysfunction
Three clinical studies were conducted in 1054 patients in an at-home setting to
define the period of responsiveness to Tadalafil. Tadalafil demonstrated
statistically significant improvement in erectile function and the ability to have
successful sexual intercourse up to 36 hours following dosing, as well as patients'
ability to attain and maintain erections for successful intercourse compared to
placebo as early as 16 minutes following dosing.
In a 12-week study performed in 186 patients (142 Tadalafil, 44 placebo) with
erectile dysfunction secondary to spinal cord injury, Tadalafil significantly
improved the erectile function leading to a mean per-subject proportion of
successful attempts in patients treated with Tadalafil 10 or 20 mg (flexible-dose,
on demand) of 48% as compared to 17% with placebo.
Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving
3250 patients, including patients with erectile dysfunction of various severities
(mild, moderate, severe), etiologies, ages (range 21-86 years), and ethnicities. Most
patients reported erectile dysfunction of at least 1 year in duration. In the primary
efficacy studies of general populations, 81% of patients reported that Tadalafil
improved their erections as compared to 35% with placebo. Also, patients with
erectile dysfunction in all severity categories reported improved erections whilst
taking Tadalafil (86%, 83%, and 72% for mild, moderate, and severe, respectively,
as compared to 45%, 42%, and 19% with placebo). In the primary efficacy studies,
75% of intercourse attempts were successful in Tadalafil-treated patients as
compared to 32% with placebo.
For once-a-day evaluation of Tadalafil at doses of 2.5, 5, and 10 mg 3 clinical
studies were initially conducted involving 853 patients of various ages (range 21-
82 years) and ethnicities, with erectile dysfunction of various severities (mild,
moderate, severe) and etiologies. In the two primary efficacy studies of general
populations, the mean per-subject proportion of successful intercourse attempts
were 57 and 67% on Tadalafil 5mg, 50% on Tadalafil 2.5mg as compared to 31 and
37% with placebo. In the study in patients with erectile dysfunction secondary to
diabetes, the mean per-subject proportion of successful attempts were 41 and 46%
on Tadalafil 5mg and 2.5mg, respectively, as compared to 28% with placebo. Most
patients in these three studies were responders to previous on-demand treatment
with PDE5 inhibitors. In a subsequent study, 217 patients who were treatmentnaive
to PDE5 inhibitors were randomised to Tadalafil 5mg once a day vs.
placebo. The mean per-subject proportion of successful sexual intercourse
attempts was 68% for Tadalafil patients compared to 52% for patients on placebo.
Benign prostatic hyperplasia
Tadalafil was studied in 4 clinical studies of 12 weeks duration enrolling over 1500
patients with signs and symptoms of benign prostatic hyperplasia. The
improvement in the total international prostate symptom score with Tadalafil 5mg
in the four studies were -4.8, -5.6, -6.1 and -6.3 compared to -2.2, -3.6, -3.8 and -4.2
with placebo. The improvements in total international prostate symptom score
occurred as early as 1 week. In one of the studies, which also included tamsulosin
0.4 mg as an active comparator, the improvement in total international prostate
symptom score with Tadalafil 5mg, tamsulosin and placebo were -6.3, -5.7 and -
4.2 respectively.
One of these studies assessed improvements in erectile dysfunction and signs and
symptoms of benign prostatic hyperplasia in patients with both conditions. The
improvements in the erectile function domain of the international index of erectile
function and the total international prostate symptom score in this study were 6.5
and -6.1 with Tadalafil 5 mg compared to 1.8 and -3.8 with placebo, respectively.
The mean per-subject proportion of successful sexual intercourse attempts was
71.9% with Tadalafil 5 mg compared to 48.3% with placebo.
The maintenance of the effect was evaluated in an open-label extension to one of
the studies, which showed that the improvement in total international prostate
symptom score seen at 12 weeks was maintained for up to 1 additional year of
treatment with Tadalafil 5mg.
Paediatric population
A single study has been performed in paediatric patients with Duchenne
Muscular Dystrophy (DMD) in which no evidence of efficacy was seen. The
randomised, double–blind, placebo–controlled, parallel, 3–arm study of Tadalafil
was conducted in 331 boys aged 7–14 years with DMD receiving concurrent
corticosteroid therapy. The study included a 48–week double-blind period where
patients were randomised to Tadalafil 0.3 mg/kg, Tadalafil 0.6 mg/kg, or placebo
daily. Tadalafil did not show efficacy in slowing the decline in ambulation as
measured by the primary 6 minute walk distance (6MWD) endpoint: least squares
(LS) mean change in 6MWD at 48 weeks was –51.0 meters (m) in the placebo
group, compared with –64.7 m in the Tadalafil 0.3 mg/kg group (p = 0.307) and –
59.1 m in the Tadalafil 0.6 mg/kg group (p = 0.538). In addition, there was no
evidence of efficacy from any of the secondary analyses performed in this study.
The overall safety results from this study were generally consistent with the
known safety profile of Tadalafil and with adverse events (AEs) expected in a
paediatric DMD population receiving corticosteroids.
The European Medicines Agency has waived the obligation to submit the results
of studies in all subsets of the paediatric population in the treatment of the erectile
dysfunction. See section 4.2 for information on paediatric use.

Absorption
Tadalafil is readily absorbed after oral administration and the mean maximum
observed plasma concentration (Cmax) is achieved at a median time of 2 hours
after dosing. Absolute bioavailability of Tadalafil following oral dosing has not
been determined.
The rate and extent of absorption of Tadalafil are not influenced by food, thus
Tadalafil may be taken with or without food. The time of dosing (morning versus
evening) had no clinically relevant effects on the rate and extent of absorption.
Distribution
The mean volume of distribution is approximately 63 liters, indicating that
Tadalafil is distributed into tissues. At therapeutic concentrations, 94% of
Tadalafil in plasma is bound to proteins. Protein binding is not affected by
impaired renal function.
Less than 0.0005% of the administered dose appeared in the semen of healthy
subjects.
Biotransformation
Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4
isoform. The major circulating metabolite is the methyl catechol glucuronide. This
metabolite is at least 13,000-fold less potent than Tadalafil for PDE5.
Consequently, it is not expected to be clinically active at observed metabolite
concentrations.
Elimination
The mean oral clearance for Tadalafil is 2.5 l/h and the mean half-life is 17.5 hours
in healthy subjects.
Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces
(approximately 61% of the dose) and to a lesser extent in the urine (approximately
36% of the dose).
Linearity/Non-Linearity
Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and
dose. Over a dose range of 2.5mg to 20mg, exposure (AUC) increases
proportionally with dose. Steady-state plasma concentrations are attained within
5 days of once daily dosing.
Pharmacokinetics determined with a population approach in patients with
erectile dysfunction are similar to pharmacokinetics in subjects without erectile
dysfunction.
Special Populations
Elderly
Healthy elderly subjects (65 years or over) had a lower oral clearance of Tadalafil,
resulting in 25% higher exposure (AUC) relative to healthy subjects aged 19 to 45
years. This effect of age is not clinically significant and does not warrant a dose
adjustment.
Renal Insufficiency
In clinical pharmacology studies using single dose Tadalafil (5mg-20mg),
Tadalafil exposure (AUC) approximately doubled in subjects with mild
(creatinine clearance 51 to 80ml/min) or moderate (creatinine clearance 31 to
50ml/min) renal impairment and in subjects with end-stage renal disease on
dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in
healthy subjects. Haemodialysis contributes negligibly to Tadalafil elimination.
Hepatic Insufficiency
Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment
(Child-Pugh class A and B) is comparable to exposure in healthy subjects when a
dose of 10mg is administered. There is limited clinical data on the safety of
Tadalafil in patients with severe hepatic insufficiency (Child-Pugh class C). If
Tadalafil is prescribed, a careful individual benefit/risk evaluation should be
undertaken by the prescribing physician. There are no available data about the
administration of doses higher than 10mg of Tadalafil to patients with hepatic
impairment. There are no available data about the administration of once-a-day
dosing of Tadalafil to patients with hepatic impairment. If Torlen is prescribed
once-a-day, a careful individual benefit/risk evaluation should be undertaken by
the prescribing physician.
Patients with Diabetes
Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower
than the AUC value for healthy subjects. This difference in exposure does not
warrant a dose adjustment.

Non-clinical data reveal no special hazard for humans based on conventional
studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic
potential, and toxicity to reproduction.
There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or
mice that received up to 1000mg/kg/day Tadalafil. In a rat prenatal and postnatal
development study, the no observed effect dose was 30mg/kg/day. In the
pregnant rat the AUC for calculated free drug at this dose was approximately 18-
times the human AUC at a 20mg dose.
There was no impairment of fertility in male and female rats. In dogs given
Tadalafil daily for 6 to 12 months at doses of 25mg/kg/day (resulting in at least a
3-fold greater exposure [range 3.7-18.6] than seen in humans given a single 20mg
dose) and above, there was regression of the seminiferous tubular epithelium that
resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.

lactose monohydrate, croscarmellose sodium, Povidone K30, Sodium Lauryl
Sulfate, Colloidal anhydrous silica, magnesium stearate, Aquapolish P.Orange

Not applicable.

2 years.

Keep out of the reach and sight of children.
Do not use Tadalafil after the expiry date stated on the carton and blister.
Do not store above 30°C.

5 mg: Alu/Alu blisters containing 30 Film coated tablets.
10 & 20 mg: Alu/Alu blisters containing 4 Film coated tablets.

No special requirements.